Epirium Bio raises $85 million

Longevity Technology Epirium

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

New kid on the block Epirium Bio raises $85 million for an innovative platform which aims to combat muscular dystrophy and aging.

Biopharmaceutical company, Epirium Bio has raised $85 million in Series A financing, from a number of investors including Laura Deming’s longevity fund as well as Arch Venture Partners and Adams Street Partners, both of which are based in Chicago. The proceeds will help it advance the development of their innovative scientific platform [1].

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 2150

Epirium Bio

Longevity level(s):

  • Level 6: Aging disease prevention therapeutics
    Therapeutic interventions that control aging drivers to prevent aging diseases from occurring, like the current wave of GLP-1 agonists that prevent type 2 diabetes through metabolic interventions that also are proving effective in mitigating cardiovascular and neurological diseases.
  • Level 7: Targeted aging disease reversal
    Therapeutic interventions that stop or reverse age-related damage in specific organs (organ specific / tissue specific / localized reversal) or for age-related diseases including technologies like partial cellular reprogramming.

Overview

Epirium Bio is a clinical-stage biopharmaceutical company developing orally bioavailable small-molecule therapeutics that modulate PGE-2 signaling to restore tissue homeostasis and promote regeneration. The company targets neuromuscular diseases, particularly sarcopenia, as well as inflammatory and fibrotic conditions including spinal muscular atrophy, irritable bowel disease, and idiopathic pulmonary fibrosis. Epirium Bio's lead candidate, MF-300, a first-in-class 15-PGDH enzyme inhibitor, is advancing through Phase 2b clinical development for sarcopenia, with the company pursuing a therapeutic approach aimed at addressing age-related muscle wasting and tissue dysfunction.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

Eleanor Garth

Editor

Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

With a keen interest in all things geroscience, Eleanor covers the biological mechanisms of aging, highlighting how interventions – from nutritional strategies to advanced therapeutics – can influence the aging process at a cellular level. She also investigates the broader implications of aging research, including the integration of longevity science into healthcare strategy and the expanding wellness economy. Her work (hopefully) provides insights into how these developments are shaping the emerging landscape of healthspan optimization and age-related innovation.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Old dogs, new funding: Dog Aging Project fetches $29m from NIH

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE